Please assess the completion status of the following clinical trial:

Trial Title: Post-licensure Safety Study of IMOJEV® in Thailand

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children requiring vaccination against Japanese encephalitis~* Children aged 9 months to less than 5 years on the day of inclusion~* In good general health at the time of inclusion~* Informed consent form has been signed and dated by the parent(s)/legal guardian(s)~* Subject and parent(s)/legal guardian(s) are able to attend the scheduled visit and any additional visits that may need to be done in case of an SAE (including AESI), and are able to comply with all trial procedures~* The subject's parent(s)/legal guardian(s) have a telephone number at which they can be contacted throughout the study~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the vaccination~* Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination~* Planned participation in another clinical trial during the present trial period~* Children previously vaccinated with the live attenuated Japanese encephalitis vaccine CD-JEVAX® (SA14-14-2 LAV)~* Contraindications to vaccination according to the IMOJEV® Summary of Product Characteristics (SmPC)~* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study~* Children who received IMOJEV® as primary vaccination in this study.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- Primary Vaccination Group (Type: EXPERIMENTAL): Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
- Booster Vaccination Group (Type: ACTIVE_COMPARATOR): Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier

Based on this trial design, predict the completion outcome and termination type (if applicable).